Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07519902

Phase 3, Randomized, Double-Masked Study of Cenegermin Eye Drops Compared With Vehicle for Persistent Corneal Epithelial Defect

Led by Dompé Farmaceutici S.p.A · Updated on 2026-06-05

150

Participants Needed

18

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of cenegermin ophthalmic solution compared with a vehicle solution in treating Persistent Corneal Epithelial Defect (PCED). This phase 3, randomized, double-masked, vehicle-controlled study aims to determine whether cenegermin can induce complete healing of the corneal epithelium after 4 weeks of treatment. The trial is sponsored by Dompé Farmaceutici S.p.A and involves multiple centers. Participants will be randomly assigned to receive either the active drug cenegermin or a vehicle solution applied topically to the affected eye. The study includes three main periods: an 8-week initial treatment phase, followed by an 8-week extension treatment phase, and then a 24-week follow-up phase to monitor ongoing effects and safety. Throughout the study, participants will undergo assessments to measure the healing of the corneal epithelium, including the proportion achieving complete healing at weeks 4 and 8. Researchers will also track changes in the size of the epithelial defect and record any adverse events or reasons for discontinuation. The total study duration for each participant is 40 weeks, with regular evaluations during treatment and follow-up periods.

CONDITIONS

Brief Title

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women aged 18 years or above (19 years or above in South Korea)
  • Persistent Corneal Epithelial Defect (PCED) in the study eye with a diameter of at least 1.0 mm
  • PCED lasting at least 14 days and not responding to one or more conventional nonsurgical treatments
  • Stable use of most topical ophthalmic medications for at least 30 days prior to the study with no expected dose changes
  • Use of prophylactic topical antibiotics up to 4 times per day if already being used before enrollment
Not Eligible

You will not qualify if you...

  • Vision of no light perception or absence of the opposite eye
  • Active eye infection or inflammation such as bacterial, fungal, or protozoal infection, infectious stromal infiltrates, or acute uveitis within 30 days
  • Corneal epithelial defect with stromal thinning greater than 30% or associated stromal infiltrate
  • Severe eyelid diseases including mechanical abnormalities contacting the defect, lagophthalmos greater than 2 mm, nocturnal lagophthalmos, Parkinson's disease, or inability to fully close eyelids
  • Severe end-stage ocular surface disease, including severe limbal stem cell deficiency or keratinization of conjunctiva or lid margin
  • Use of specific medications or devices within defined time windows prior to randomization, including prior cenegermin use, blood-derived eye drops, topical anesthetics outside exams, botox injections, systemic corticosteroids, systemic opioids, investigational products, chemotherapy, or contact lenses
  • Anticipated need for punctal occlusion during the study period
  • Severe systemic diseases affecting participation
  • Recent major eye surgery or amniotic membrane therapy within 14 days
  • Partial tarsorrhaphy placed within 14 days unless maintained during the study period
  • Additional exclusion criteria as defined in the protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 8 weeks

Participants receive either cenegermin ophthalmic solution or vehicle ophthalmic solution administered topically to the study eye.

Visits at baseline, Week 4, and Week 8 for assessments

Trial Site Locations

Total: 18 locations

1

Azul Vision, INC

Huntington Beach, California, United States, 92647

Not Yet Recruiting

2

Harvard Eye Associates

Laguna Hills, California, United States, 92653

Actively Recruiting

3

Loma Linda University Adventist Health Sciences Center

Loma Linda, California, United States, 92354

Not Yet Recruiting

4

UCLA - Jules Stein Eye Institute (JSEI) - Diabetic Eye Dise

Los Angeles, California, United States, 90095

Not Yet Recruiting

5

California Eye Specialists Medical Group, Inc.

Redlands, California, United States, 92373

Not Yet Recruiting

6

East Coast Institute for Research - Florida Eye Specialists

Jacksonville, Florida, United States, 32207

Actively Recruiting

7

Bascom Palmer Eye Institute, University of Miami School of Medicine

Miami, Florida, United States, 33136

Actively Recruiting

8

University of South Florida

Tampa, Florida, United States, 33620

Actively Recruiting

9

Massachusetts Eye and Ear

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

10

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States, 02114

Actively Recruiting

11

University of Michigan Health - Kellogg Eye Center

Ann Arbor, Michigan, United States, 48105

Not Yet Recruiting

12

Midwest Vision Research Foundation

Chesterfield, Missouri, United States, 63017

Actively Recruiting

13

NYU Langone Eye Center (Ophthalmology)

New York, New York, United States, 10017

Not Yet Recruiting

14

Duke Eye Center - Ophthalmology

Durham, North Carolina, United States, 27705

Not Yet Recruiting

15

Vance Thompson Vision - Sioux Falls

Sioux Falls, South Dakota, United States, 57108

Actively Recruiting

16

Houston Eye Associates (HEA)

Houston, Texas, United States, 77030

Actively Recruiting

17

The Eye Institute of Utah

Salt Lake City, Utah, United States, 84107

Actively Recruiting

18

Virginia Eye Consultants

Norfolk, Virginia, United States, 23502

Actively Recruiting

Loading map...

Research Team

D

Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Randomized, Double-Masked, Vehicle-Controlled Study to Eva...

Persistent Corneal Epithelial Defect

Actively Recruiting

28 locations

Comparison of Efficacy of Topical Insulin With Amniotic Memb...

Persistent Corneal Epithelial Defect

Actively Recruiting

1 location

Phase II Study of the Efficacy of Topical Mesenchymal Stroma...

Persistent Corneal Epithelial Defect

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here